Stevens Capital Management LP lessened its holdings in NuVasive, Inc. (NASDAQ:NUVA) by 81.7% in the second quarter, HoldingsChannel.com reports. The firm owned 3,986 shares of the medical device company’s stock after selling 17,803 shares during the period. Stevens Capital Management LP’s holdings in NuVasive were worth $208,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
A number of other large investors have also made changes to their positions in the business. Champlain Investment Partners LLC grew its stake in shares of NuVasive by 9.6% during the 1st quarter. Champlain Investment Partners LLC now owns 3,140,110 shares of the medical device company’s stock worth $163,945,000 after acquiring an additional 273,863 shares during the period. Eagle Asset Management Inc. grew its stake in shares of NuVasive by 12.8% during the 2nd quarter. Eagle Asset Management Inc. now owns 1,267,961 shares of the medical device company’s stock worth $66,086,000 after acquiring an additional 143,926 shares during the period. Dimensional Fund Advisors LP grew its stake in shares of NuVasive by 23.0% during the 1st quarter. Dimensional Fund Advisors LP now owns 1,181,636 shares of the medical device company’s stock worth $61,693,000 after acquiring an additional 221,153 shares during the period. Anchor Capital Advisors LLC grew its stake in shares of NuVasive by 1,205.1% during the 2nd quarter. Anchor Capital Advisors LLC now owns 983,977 shares of the medical device company’s stock worth $51,285,000 after acquiring an additional 908,582 shares during the period. Finally, Hood River Capital Management LLC grew its stake in shares of NuVasive by 261.3% during the 2nd quarter. Hood River Capital Management LLC now owns 866,653 shares of the medical device company’s stock worth $45,170,000 after acquiring an additional 626,770 shares during the period.
A number of analysts recently issued reports on NUVA shares. Cantor Fitzgerald started coverage on NuVasive in a report on Thursday, May 31st. They set a “neutral” rating and a $54.00 price objective on the stock. Zacks Investment Research raised NuVasive from a “sell” rating to a “hold” rating in a report on Tuesday, August 21st. BidaskClub raised NuVasive from a “hold” rating to a “buy” rating in a report on Friday, June 15th. ValuEngine raised NuVasive from a “strong sell” rating to a “sell” rating in a report on Monday, July 30th. Finally, BTIG Research increased their price objective on NuVasive to $72.00 and gave the stock a “buy” rating in a report on Thursday, August 16th. Two analysts have rated the stock with a sell rating, ten have issued a hold rating and nine have issued a buy rating to the stock. NuVasive currently has an average rating of “Hold” and an average price target of $64.06.
NASDAQ:NUVA opened at $70.43 on Thursday. NuVasive, Inc. has a twelve month low of $44.62 and a twelve month high of $71.15. The stock has a market capitalization of $3.61 billion, a price-to-earnings ratio of 36.87, a price-to-earnings-growth ratio of 1.93 and a beta of 0.69.
NuVasive (NASDAQ:NUVA) last released its quarterly earnings results on Tuesday, July 31st. The medical device company reported $0.58 earnings per share for the quarter, meeting the consensus estimate of $0.58. NuVasive had a return on equity of 13.70% and a net margin of 3.96%. The firm had revenue of $281.56 million for the quarter, compared to analysts’ expectations of $276.05 million. equities research analysts forecast that NuVasive, Inc. will post 2.39 earnings per share for the current year.
NuVasive, Inc, a medical device company, develops and markets minimally-disruptive surgical products and procedurally-integrated solutions for spine surgery. Its products focus on applications for spine fusion surgery, including ancillary products and services used to aid in the surgical procedure. The company's principal product is Maximum Access Surgery, a minimally-disruptive surgical platform, which includes its software-driven nerve detection and avoidance systems, and intraoperative monitoring (IOM) services and support; MaXcess, an integrated split-blade retractor system; and various specialized implants and biologics.
Featured Story: How to Invest in Growth Stocks
Want to see what other hedge funds are holding NUVA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for NuVasive, Inc. (NASDAQ:NUVA).
Receive News & Ratings for NuVasive Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NuVasive and related companies with MarketBeat.com's FREE daily email newsletter.